Aikido Pharma Inc - ESG Rating & Company Profile powered by AI
This Disclosure score covers 17 United Nations Sustainable Development Goals including: 'Zero Hunger', 'Climate Action' and 'Life on Land'. Alternative corporations in the scoring peer group for Aikido Pharma Inc are displayed. This webpage displays a free Sustainability analysis covering Aikido Pharma Inc.
Aikido Pharma Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 1.5; made up of an environmental score of 0.0, social score of 0.0 and governance score of 4.6.
1.5
Low ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Novartis AG | 9.2 | High |
| 2 | Daiichi Sankyo Co Ltd | 8.9 | High |
| ... | ... | ... | |
| 2329 | Veritas Pharma Inc | 1.6 | Low |
| 2329 | Zhejiang Xinguang Pharmaceutical Co Ltd | 1.6 | Low |
| 2372 | Aikido Pharma Inc | 1.5 | Low |
| 2372 | Ambrx Biopharma Inc | 1.5 | Low |
| 2372 | Ahlcon Parenterals (India) Ltd | 1.5 | Low |
| 2749 | Xynomic Pharmaceuticals Holdings Inc | 0.0 | Low |
| 2749 | Zyden Gentec Ltd | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Aikido Pharma Inc have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Aikido Pharma Inc disclose current and historical energy intensity?
Sign up for free to unlockDoes Aikido Pharma Inc report the average age of the workforce?
Sign up for free to unlockDoes Aikido Pharma Inc reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Aikido Pharma Inc disclose its ethnicity pay gap?
Sign up for free to unlockDoes Aikido Pharma Inc disclose cybersecurity risks?
Sign up for free to unlockDoes Aikido Pharma Inc offer flexible work?
Sign up for free to unlockDoes Aikido Pharma Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Aikido Pharma Inc disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Aikido Pharma Inc conduct supply chain audits?
Sign up for free to unlockDoes Aikido Pharma Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Aikido Pharma Inc conduct 360 degree staff reviews?
Sign up for free to unlockDoes Aikido Pharma Inc disclose the individual responsible for D&I?
Sign up for free to unlockDoes Aikido Pharma Inc disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Aikido Pharma Inc disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Aikido Pharma Inc disclose water use targets?
Sign up for free to unlockDoes Aikido Pharma Inc have careers partnerships with academic institutions?
Sign up for free to unlockDid Aikido Pharma Inc have a product recall in the last two years?
Sign up for free to unlockDoes Aikido Pharma Inc disclose incidents of discrimination?
Sign up for free to unlockDoes Aikido Pharma Inc allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Aikido Pharma Inc issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Aikido Pharma Inc disclose parental leave metrics?
Sign up for free to unlockDoes Aikido Pharma Inc disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Aikido Pharma Inc disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Aikido Pharma Inc disclose the pay ratio of women to men?
Sign up for free to unlockDoes Aikido Pharma Inc support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Aikido Pharma Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Aikido Pharma Inc reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Aikido Pharma Inc involved in embryonic stem cell research?
Sign up for free to unlockDoes Aikido Pharma Inc disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Aikido Pharma Inc disclose its waste policy?
Sign up for free to unlockDoes Aikido Pharma Inc report according to TCFD requirements?
Sign up for free to unlockDoes Aikido Pharma Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Aikido Pharma Inc disclose energy use targets?
Sign up for free to unlockDoes Aikido Pharma Inc disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Aikido Pharma Inc have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Aikido Pharma Inc
These potential risks are based on the size, segment and geographies of the company.
AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavirus and Marburg virus, SARS-CoV, MERS-CoV, and SARS-CoV-2. It has license agreements with the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. The company was formerly known as Spherix Incorporated and changed its name to AIkido Pharma Inc. in March 2021. AIkido Pharma Inc. was founded in 1967 and is headquartered in New York, New York.